Harpoon Therapeutics Provides an Update on the HPN217 Develo

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has

Related Keywords

Athens , Attikír , Greece , Julie Eastland , Roberth Uhl , Harpoon Therapeutics Inc , Exchange Commission , European Society For Medical Oncology , International Myeloma Society , Option Agreement , Annual Meeting , European Society , Medical Oncology , Activating Construct , Harpoon Therapeutics , Private Securities Litigation Reform Act , Harpoon Therapeutic ,